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We have recently shown that (z-MAPI, a peptidic aldehyde of microbial origin, inhibits the HIV protease with a potency comparable to pepstatin, 
having, differently from pepstatin, no activity on other aspartic proteases. In this study different peptide derivatives containing a C-terminal 
aldehyde have been tested to assess the potential of this function for the inhibition of HIV protease. The results of our analysis correspond with 
the recently published subsite preferences of the viral enzyme, indicating that aldehydes bind to the active site of the HIV protease. Our data suggest 
that peptide aldehydes can act in their hydrated forms as transition state analogues with the most potent inhibitor having an It&, of 0.9 PM. 
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1. INTRODUCTION 
The human immunodeficiency virus (HIV) aspartic 
protease is essential for the processing of the viral poly- 
proteins, playing a crucial role in the HIV life cycle. It 
is therefore considered an appealing target for the treat- 
ment of AIDS [1,2]. 
We have recently reported the isolation and struc- 
tural characterization of an HIV protease inhibitor 
from the fermentation broth of a Streptomyces strain 
[3,4]. The same molecule had been previously discov- 
ered as an inhibitor of subtilisin and other microbial 
serine proteases, with no activity on pepsin or other 
acidic proteases, and hence named a-microbial alkaline 
protease inhibitor (a-MAPI, [5,6]). However, the inhibi- 
tion of HIV protease, an acidic protease, by a-MAP1 
(IC50 = 2 PM at pH 6.0) is comparable to pepstatin 
(IC,, = 4.5 ,uM at pH 6.0) a well-known natural inhib- 
itor of the viral enzyme [3]. a-MAP1 is a tetrapeptide 
derivative with a C-terminal phenylalanine in the alde- 
hyde form [4,6]. This function is essential for the inhibi- 
tion of HIV protease, as indicated by the complete loss 
of activity which follows its oxidation to carboxylic acid 
or reduction to alcohol [3,4]. 
Peptide aldehydes are well-known inhibitors of serine 
and cysteine proteases. They react with these proteases 
to yield, respectively, hemiacetals or hemithioacetals 
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which mimic the structure of the reaction transition 
state [7-lo]. Conversely, little is known about peptide 
aldehydes as inhibitors of aspartic proteases, even 
though aldehydic inhibitors of renin have been reported 
[11,12]. These studies suggest that aspartic proteases 
may be inhibited by peptide aldehydes acting in their 
tetrahedral hydrated forms as transition state ana- 
logues. The inhibition of HIV protease by a-MAP1 
probably occurs by the same mechanism. This is sup- 
ported by the observation that valine and phenylalan- 
ine, the two C-terminal amino acid residues of a-MAPI, 
are among the best suited to occupy, respectively, the 
S, and S, sub-sites of HIV protease [ 13-151. 
In this study, to investigate the potential of the alde- 
hyde function for inhibition of HIV protease, different 
peptide derivatives were synthesized and tested on the 
viral enzyme, pepsin and cathepsin D. 
2. MATERIALS AND METHODS 
2.1. Natural products and calpain inhrbltors 
a- and B-MAP1 were isolated from the fermentation broth of a 
Streptomyces strain, as previously described [4]. Pepstatin. leupeptin 
and calpain inhibitors 1 and 2 were from Calbiochem (San Diego, 
CA); antipain and calpeptin were from Novabiochem (Switzerland); 
elastatinal was from Sigma (St. Louis, MO). 
2.2. Chemical synthesis 
The modified peptides described in this study were synthesized as 
follows. 
The compounds listed in Table II (with the exception of calpeptin) 
were prepared starting from the respective N-protected dipeptide and 
following the procedure described in [16]. Briefly, the C-terminus was 
transformed into aldehyde by reaction with N,O-dimethyl-hydroxyl- 
amine and reduction of the corresponding N-methoxy-methyl-amide 
with lithium aluminium hydride. 
The compounds listed in Table III were prepared by reaction of the 
dipeptide HzN-Val-Phe-OH with the suitable acyl chlorides at pH 9.5 
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to produce the N-acylated dipeptides. These intermediates were then 
transformed into the corresponding aldehydes following the same 
procedure as above [16]. 
The structures of all compounds were confirmed by IR, NMR and 
MS spectra. 
2.3. Protease assays 
The inhibition of HIV protease activity was assayed using the sohd- 
phase immunoassay previously described [3]. The only difference was 
the pH of the incubation solution (5.6 instead of 6.0). as explained in 
section 3.1. 
The inhibition of pepsin and cathepsin D activities was assayed with 
the same solid-phase immunoassay, at pH 5.6, using, respectively, 
pepsin (2 &ml) or cathepsin D (0.2 U/ml), both from Sigma, in place 
of the HIV protease. This was possible as it was previously found that 
the same substrate used for HIV protease, the gal-gag1 0 fusion pro- 
tein [3], contains cleavage sites for both proteases (unpublished re- 
sults). 
The values shown in the Tables are derived from at least two sepa- 
rate experiments for each compound. 
3. RESULTS 
3.1. Natural products and calpain inhibitors 
As a first approach, a number of known peptide alde- 
hydes were tested for inhibition of HIV protease, pepsin 
and cathepsin D. Table I shows the results obtained 
with five natural products and two synthetic com- 
pounds, calpain inhibitors 1 and 2 (CI- 1 and CI-2, [ 171) 
compared with pepstatin, used as control. The same pH 
(5.6) was used for all three proteases in order to avoid 
any complication due to the pH dependence of inhib- 
itors (reported, for instance, for pepstatin in [18,19]). At 
this pH the HIV protease has maximum activity [ 18-211 
and both pepsin and cathepsin D are still quite active. 
The data shown in Table I indicate that: (a) the C- 
terminal amino acid of a-MAP1 has a crucial role for 
the inhibition of HIV protease. Comparison of a-MAP1 
and antipain shows that the activity is completely lost 
when only the C-terminal, aldehyde-containing amino 
acid residue is substituted. A similar effect is observed 
comparing leupeptin with CI-1 and CI-2; (b) the re- 
quirement for phenylalanine for the C-terminal position 
is not absolute. The inhibitory activities of CI-1 and 
CI-2 show that other relatively large hydrophobic 
amino acids can replace it; (c) not only the identity, but 
also the stereochemistry of the C-terminal amino acid 
is important, as shown by the different activities of CI- 
MAP1 and /I-MAPI. 
3.2. Cbz-dipeptide aldehydes 
The results shown in Table I led us into a more sys- 
tematic study on the effects of amino acid substitutions 
in peptide aldehydes as inhibitors of HIV protease. A 
panel of carbobenzoxy (Cbz)-protected ipeptide alde- 
hydes were synthesized, in which either the phenylalan- 
ine in P, or the valine in P, were substituted. Table II 
shows the inhibitory activity of these compounds, to- 
gether with Cbz-Leu-Nle-H, or calpeptin, another cal- 
pain inhibitor [22]. 
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These data indicate that: (a) the replacement of the 
Phe-ureido-Arg-portion of a-MAP1 with Cbz has mini- 
mal effect on HIV protease inhibition, as shown by the 
ICsO values of a-MAP1 (2.7 PM, Table I) and Cbz-Val- 
Phe-H (2.9 PM, Table II); (b) in the Cbz-Val-Xaa-H 
series, the substitution of phenylalaninal with tyrosinal 
does not significantly affect the activity on the HIV 
protease while tryptophanal has a more pronounced 
effect. With the alaninal analogue the inhibitory activity 
is completely lost; (c) in the Cbz-Yaa-Phe-H series, the 
substitution of valine with isoleucine causes a slightly 
lower activity on HIV protease and the appearance of 
some activity on cathepsin D. If instead Yaa is either a 
bulky residue, like phenylalanine, or one too small, like 
alanine, the IC,, on HIV protease is one order of mag- 
nitude higher. 
3.3. R- Val-Phe-aldehydes 
Once established that the C-terminal sequence -Val- 
Table I 
Inhibition of aspartic proteases 
HIV protease Pepsin Cathepsin D 
NATURAL PRODUCTS 
Iva-Val-Val-Sta-Ala-Sta 
Pepstatin 
Phe 
o=c 
-Arg-Val-L-Phe-H 
a-MAPI 
Phe 
o=c 
Arg-Val-o-Phe-H 
p-MAPI 
Phe 
o=c- 
-Arg-Val-Arg-H 
Antiparn 
Leu 
o=c- 
-Cpd-Gln-Ala-H 
Elastatinal 
Ac-Leu-Leu-Arg-H 
Leupeptln 
CALPAIN INHIBITORS 
Ac-Leu-Leu-Nle-H 
CI-I 
Ac-Leu-Leu-Met-H 
CI-2 
2.0 <0.005 co.04 
2.7 >200 >200 
45 
>200 
>200 
>200 
5.2 
4.9 
>200 >200 
>200 >200 
>200 >200 
>200 >200 
24 35 
>200 >200 
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Table II 
Inhibition of aspartic proteases 
ICso CuM) 
Cbz-dipeptide-aldehydes 
HIV protease Pepsin Cathepsin D 
Cbz-Val-Phe-H 
Cbz-Val-Tyr-H 
Cbz-Val-Trp-H 
Cbz-Val-Ala-H 
Cbz-Ile-Phe-H 
Cbz-Phe-Phe-H 
Cbz-Ala-Phe-H 
Cbz-Leu-Nle-H 
Calpeptin 
2.9 >200 >200 
3.8 >200 >200 
21 >200 >200 
>200 >200 >200 
4.8 >200 20 
31 >200 >200 
40 >200 >200 
160 >200 >200 
Phe-H is the most active among the peptide aldehydes 
tested, we addressed the question of whether different 
N-substituents of valine might yield a higher activity on 
the HIV protease. 
Table III shows the inhibition of the three aspartic 
proteases by a series of R-Val-Phe-H compounds. 
When compared with a-MAP1 (Table I) or Cbz-Val- 
Phe-H (Table II), small alkyl groups in the R- position 
give lower activity on HIV protease. In addition, some 
activity on cathepsin D appears. 
The observation that the substitution of Cbz in cal- 
peptin (Table II) with N-Ac-Leu- in CI-1 (Table I) re- 
sults in a 30-fold lower IC,, on HIV protease, led us to 
synthesize the tripeptide N-Ac-Leu-Val-Phe-H. As 
shown in Table III, the IC,O value of this compound on 
the viral enzyme is about 3-fold lower than a-MAP1 
(Table I) or Cbz-Val-Phe-H (Table II). However, speci- 
ficity is decreased as the activity on cathepsin D is also 
higher and even some activity on pepsin appears. 
4. DISCUSSION 
The observations derived from this study yield valua- 
Table III 
Inhibition of aspartic proteases 
1% 01M) 
HIV protease Pepsin Cathepsin D 
R- Val-Phe-aldehydes 
Me-CO-Val-Phe-H 5.4 >200 40 
nPr-CO-Val-Phe-H 12 >200 60 
iPr-CO-Val-Phe-H 17 >200 100 
nNon-CO-Val-Phe-H 17 >200 72 
N-Ac-LenVal-Phe-H 0.9 100 37 
ble information on the inhibition of the HIV protease 
by peptide aldehydes. Such observations are particu- 
larly interesting if examined in the light of recent studies 
on the viral enzyme [13-l 51. These studies, based on 
substrate analogs, show that hydrophobic/aromatic 
moieties are preferable in the Si subsite of the enzyme, 
with Phe, Tyr and Met as best residues. Small polar or 
apolar, preferably B-branched, amino acids are instead 
well suited for the S, position, while a large variety of 
residues, but not proline, can occupy the S3 subsite. 
Our results indicate that &-MAP1 and the other pep- 
tide aldehydes of this study show the structure-activity 
relationship expected from inhibitors acting as substrate 
analogs. As a consequence, the aldehyde function or its 
hydrated form is located exactly in the S,/S; catalytic 
site. 
Fluorine nuclear magnetic resonance studies have 
shown that in aqueous solutions N-Ac-p-F-Phe-H is 
about 90% in the hydrated form [23]. For compounds 
like a-MAP1 the ratio between the two forms is proba- 
bly not very different. It is reasonable to suppose that 
the real inhibitors of the HIV protease are the hydrated 
forms of our peptide aldehydes. 
Aspartic proteases are believed to work by a general 
acid-base mechanism, in which a water molecule at- 
tacks the carbonyl of the scissile bond with the active- 
site Asp residues mediating the appropriate proton 
transfers [24,25]. The tetrahedral hydrated forms of 
peptide aldehydes can inhibit this reaction acting as 
transition state analogues. This mechanism can explain 
the relatively high inhibitory activities shown by com- 
pounds with only two residues for subsite recognition 
(Tables II and III). Indeed, Table III shows that the 
addition of a third residue results in a further improve- 
ment of this activity. 
In conclusion, peptide aldehydes are reagents rela- 
tively easy to prepare and at the same time very useful 
for the study of the inhibition of the HIV protease. 
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